Skip to main content
Equibles
MLSS logo

MLSS · Milestone Scientific Inc. · Metrics

Track MLSS — free

Use MLSS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLSS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.31 +0.01 (+4.50%) Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred recurring operating losses and has an accumulated deficit. These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Management believes that existing cash resources, anticipated collections and potential financing proceeds may support near-term operations; however, additional financing is required, and there can be no assurance that such financing will be available on acceptable terms, or at all. Accordingly, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”
View the 10-Q filed Aug 13, 2026
Market Cap
$26.62M
Shares
88.74M
Volume · Oct 28 29.69K Avg daily vol (3M) 119.42K

MLSS metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.30
Market cap
$26.62M

Price action

20 metrics
Price change (1W)
-11.3%
Price change (30D)
-26.8%
Price change (3M)
-30.2%
Price change (6M)
-9.1%
Price change (YTD)
+11.1%
Price change (1Y)
-34.8%
Trailing year
Price change (5Y)
-84.8%
52-week high
$0.55
52-week low
$0.25
Change from 52-week high
-45.5%
Change from 52-week low
+20.0%
Annualized volatility
80.2%
Annualized volatility (3M)
67.3%
Beta
1.0
RSI (14D)
25.4
Price vs SMA 50
-26.0%
Price vs SMA 200
-15.3%
Avg volume (3M)
119,415
Relative volume
0.4
Average dollar volume
$52,878

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
88.74M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.1%
P / book
7.7
reciprocal yield 12.9%
FCF yield
-2.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-31

Profitability

9 metrics
Gross margin
70.2%
Operating margin
-43.6%
Trailing 12 months
Net margin
-44.0%
Gross profit (TTM)
$6.62M
Operating profit (TTM)
−$4.10M
Net income (TTM)
−$4.14M
Trailing 12 months
Diluted EPS (TTM)
$-0.05
FCF margin
-7.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.11
Gross profit per diluted share (TTM)
$0.08
Operating profit per diluted share (TTM)
$-0.05
EBITDA per diluted share (TTM)
$-0.05
Net income per diluted share (TTM)
$-0.05
Operating cash flow per diluted share (TTM)
$-0.01
Free cash flow per diluted share (TTM)
$-0.01
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.01
Book value per share
$0.03

Growth

11 metrics
Revenue growth YoY
+22.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+13.5%
Year over year · more shares
Revenue CAGR (3Y)
+0.6%
Revenue CAGR (5Y)
+10.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-119.4%
Return on assets
-49.6%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
−$4.03M
Free cash flow (TTM)
−$657,758
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.20M
Latest balance sheet
Cash & equivalents
$1.20M
Total assets
$8.35M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$642,639
Capital expenditures (TTM)
$15,119
R&D (TTM)
$35,169
SG&A (TTM)
$10.61M
Stock compensation (TTM)
$1.03M
R&D / revenue
—
Stock compensation / revenue
10.9%

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
-3
Institutional ownership
5.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.5%
Private-fund adviser ownership
0.4%
Active holders' share change QoQ
-18.4%
Holder tenure
9.8
Price vs estimated holder cost
-65.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.9%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
25 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 855683 CUSIP 59935P209 13F (30d) 4 filings 4 filers Visit website Investor relations